semaglutide glp-1 medication GLP-1s GLP-1 Weight Loss Options |

If a doctor prescribed Ozempic off-label for weight loss without adequately considering its risks or without providing appropriate warnings, affected patients might have a malpractice claim

In the NEC Baby Formula Lawsuits, liability is primarily focused on the manufacturers of cows milk-based formulas, such as Abbott Laboratories (Similac) and Mead Johnson (Enfamil)

1 Introduction Substance use disorders (SUDs) represent a major global public health challenge, contributing significantly to morbidity, premature mortality, and socioeconomic burdens ( One promising strategy involves repurposing existing medications with well-established safety profiles ( Despite promising findings in animal studies, human studies remain limited

You may be eligible if you: Are aged 18 or older, either with or without type 2 diabetes, with a BMI of 27 or greater Have been diagnosed with chronic kidney disease Either have an eGFR between 25-60, or an eGFR between 25-75 with a UACR of more than 30 Have been receiving an angiotensin-converting enzyme (ACE) or angiotensin II receptor blockers (ARB) that is considered the maximum appropriate dose for treatment of chronic kidney disease or hypertension (unless the participant has low blood pressure or hypotension) Have an A1C of below 6.5 (if you do not have type 2 diabetes) Have an A1C of below 9.5 (if you do have type 2 diabetes), as well as a diabetes diagnosis that occurred more than 180 days prior to screening People who have lost or gained more than 11 pounds (5 kg) within 90 days of screening, people with type 1 diabetes, and people who have had or plan to have bariatric surgery or device-based therapy for obesity may not be eligible to participate